ID   KAPCB_HUMAN             Reviewed;         351 AA.
AC   P22694; B1APG4; B4DKB0; B4E2Q1; Q14VH1; Q59GC0; Q5BNE9; Q5BNF0; Q5BNF1;
AC   Q5BNF2; Q5BNF3; Q5CZ92; Q5T1K3; Q7Z3M1; Q8IYR5; Q8IZQ0; Q96B09;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   12-OCT-2022, entry version 223.
DE   RecName: Full=cAMP-dependent protein kinase catalytic subunit beta;
DE            Short=PKA C-beta;
DE            EC=2.7.11.11;
GN   Name=PRKACB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RX   PubMed=2342480; DOI=10.1210/mend-4-3-465;
RA   Beebe S.J., Oyen O., Sandberg M., Froysa A., Hansson V., Jahnsen T.;
RT   "Molecular cloning of a tissue-specific protein kinase (C gamma) from human
RT   testis -- representing a third isoform for the catalytic subunit of cAMP-
RT   dependent protein kinase.";
RL   Mol. Endocrinol. 4:465-475(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 7).
RC   TISSUE=Retina, and Salivary gland;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 6).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3; 9 AND 10).
RC   TISSUE=Brain, Thalamus, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUN-2006) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 8).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-30 (ISOFORMS 2; 5 AND 6), NUCLEOTIDE
RP   SEQUENCE [MRNA] OF 1-16 (ISOFORM 3), NUCLEOTIDE SEQUENCE [MRNA] OF 1-13
RP   (ISOFORM 4), AND TISSUE SPECIFICITY.
RX   PubMed=11589697; DOI=10.1046/j.0014-2956.2001.02429.x;
RA   Orstavik S., Reinton N., Frengen E., Langeland B.T., Jahnsen T.,
RA   Skalhegg B.S.;
RT   "Identification of novel splice variants of the human catalytic subunit
RT   Cbeta of cAMP-dependent protein kinase.";
RL   Eur. J. Biochem. 268:5066-5073(2001).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-15 (ISOFORM 1), AND FUNCTION.
RX   PubMed=12420224; DOI=10.1038/sj.onc.1205986;
RA   Wu K.-J., Mattioli M., Morse H.C., Dalla-Favera R.;
RT   "c-MYC activates protein kinase A (PKA) by direct transcriptional
RT   activation of the PKA catalytic subunit beta (PKA-CB) gene.";
RL   Oncogene 21:7872-7882(2002).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH GPKOW.
RX   PubMed=21880142; DOI=10.1186/1750-2187-6-10;
RA   Aksaas A.K., Larsen A.C., Rogne M., Rosendal K., Kvissel A.K.,
RA   Skaalhegg B.S.;
RT   "G-patch domain and KOW motifs-containing protein, GPKOW; a nuclear RNA-
RT   binding protein regulated by protein kinase A.";
RL   J. Mol. Signal. 6:10-10(2011).
RN   [14]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH PJA2.
RX   PubMed=21423175; DOI=10.1038/ncb2209;
RA   Lignitto L., Carlucci A., Sepe M., Stefan E., Cuomo O., Nistico R.,
RA   Scorziello A., Savoia C., Garbi C., Annunziato L., Feliciello A.;
RT   "Control of PKA stability and signalling by the RING ligase praja2.";
RL   Nat. Cell Biol. 13:412-422(2011).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [16]
RP   MYRISTOYLATION AT GLY-2, CLEAVAGE OF INITIATOR METHIONINE, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=25255805; DOI=10.1038/ncomms5919;
RA   Thinon E., Serwa R.A., Broncel M., Brannigan J.A., Brassat U., Wright M.H.,
RA   Heal W.P., Wilkinson A.J., Mann D.J., Tate E.W.;
RT   "Global profiling of co- and post-translationally N-myristoylated proteomes
RT   in human cells.";
RL   Nat. Commun. 5:4919-4919(2014).
RN   [17]
RP   VARIANT [LARGE SCALE ANALYSIS] GLN-106.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [18]
RP   VARIANTS CAFD2 LEU-54; ARG-88; ASN-88 AND ARG-235, INVOLVEMENT IN CAFD2,
RP   CHARACTERIZATION OF VARIANTS CAFD2 ARG-88 AND ARG-235, INTERACTION WITH
RP   PRKAR1A AND PRKAR2B, AND ACTIVITY REGULATION.
RX   PubMed=33058759; DOI=10.1016/j.ajhg.2020.09.005;
RA   Palencia-Campos A., Aoto P.C., Machal E.M.F., Rivera-Barahona A.,
RA   Soto-Bielicka P., Bertinetti D., Baker B., Vu L., Piceci-Sparascio F.,
RA   Torrente I., Boudin E., Peeters S., Van Hul W., Huber C., Bonneau D.,
RA   Hildebrand M.S., Coleman M., Bahlo M., Bennett M.F., Schneider A.L.,
RA   Scheffer I.E., Kibaek M., Kristiansen B.S., Issa M.Y., Mehrez M.I.,
RA   Ismail S., Tenorio J., Li G., Skaalhegg B.S., Otaify G.A., Temtamy S.,
RA   Aglan M., Joench A.E., De Luca A., Mortier G., Cormier-Daire V.,
RA   Ziegler A., Wallis M., Lapunzina P., Herberg F.W., Taylor S.S.,
RA   Ruiz-Perez V.L.;
RT   "Germline and Mosaic Variants in PRKACA and PRKACB Cause a Multiple
RT   Congenital Malformation Syndrome.";
RL   Am. J. Hum. Genet. 107:977-988(2020).
CC   -!- FUNCTION: Mediates cAMP-dependent signaling triggered by receptor
CC       binding to GPCRs. PKA activation regulates diverse cellular processes
CC       such as cell proliferation, the cell cycle, differentiation and
CC       regulation of microtubule dynamics, chromatin condensation and
CC       decondensation, nuclear envelope disassembly and reassembly, as well as
CC       regulation of intracellular transport mechanisms and ion flux.
CC       Regulates the abundance of compartmentalized pools of its regulatory
CC       subunits through phosphorylation of PJA2 which binds and ubiquitinates
CC       these subunits, leading to their subsequent proteolysis
CC       (PubMed:12420224, PubMed:21423175). Phosphorylates GPKOW which
CC       regulates its ability to bind RNA (PubMed:21880142).
CC       {ECO:0000269|PubMed:12420224, ECO:0000269|PubMed:21423175,
CC       ECO:0000269|PubMed:21880142}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.11;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.11;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ACTIVITY REGULATION: Activated by cAMP. {ECO:0000269|PubMed:33058759}.
CC   -!- SUBUNIT: A number of inactive tetrameric holoenzymes are produced by
CC       the combination of homo- or heterodimers of the different regulatory
CC       subunits associated with two catalytic subunits. cAMP causes the
CC       dissociation of the inactive holoenzyme into a dimer of regulatory
CC       subunits bound to four cAMP and two free monomeric catalytic subunits
CC       (By similarity). Interacts with PRKAR1A and PRKAR2B (PubMed:33058759).
CC       The cAMP-dependent protein kinase catalytic subunit binds PJA2
CC       (PubMed:21423175). Interacts with GPKOW (PubMed:21880142).
CC       {ECO:0000250|UniProtKB:P05132, ECO:0000269|PubMed:21423175,
CC       ECO:0000269|PubMed:21880142, ECO:0000269|PubMed:33058759}.
CC   -!- INTERACTION:
CC       P22694; P05067: APP; NbExp=3; IntAct=EBI-2679622, EBI-77613;
CC       P22694; Q92624: APPBP2; NbExp=3; IntAct=EBI-2679622, EBI-743771;
CC       P22694; Q5T686: AVPI1; NbExp=3; IntAct=EBI-2679622, EBI-8640233;
CC       P22694; P08238: HSP90AB1; NbExp=2; IntAct=EBI-2679622, EBI-352572;
CC       P22694; P61925: PKIA; NbExp=5; IntAct=EBI-2679622, EBI-2682139;
CC       P22694-2; Q92917: GPKOW; NbExp=4; IntAct=EBI-5258763, EBI-746309;
CC       P22694-8; P05067: APP; NbExp=3; IntAct=EBI-25937151, EBI-77613;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:21423175}. Cell
CC       membrane {ECO:0000269|PubMed:21423175}. Membrane {ECO:0000305}; Lipid-
CC       anchor {ECO:0000305}. Nucleus {ECO:0000250}. Note=Translocates into the
CC       nucleus (monomeric catalytic subunit). The inactive holoenzyme is found
CC       in the cytoplasm. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=10;
CC       Name=1; Synonyms=Beta1;
CC         IsoId=P22694-1; Sequence=Displayed;
CC       Name=2; Synonyms=Beta2;
CC         IsoId=P22694-2; Sequence=VSP_017364;
CC       Name=3; Synonyms=Beta3;
CC         IsoId=P22694-3; Sequence=VSP_017369, VSP_017370;
CC       Name=4; Synonyms=Beta4;
CC         IsoId=P22694-4; Sequence=VSP_017368, VSP_017371;
CC       Name=5; Synonyms=Beta4ab;
CC         IsoId=P22694-5; Sequence=VSP_017366;
CC       Name=6; Synonyms=Beta4abc;
CC         IsoId=P22694-6; Sequence=VSP_017365;
CC       Name=7;
CC         IsoId=P22694-7; Sequence=VSP_017367;
CC       Name=8;
CC         IsoId=P22694-8; Sequence=VSP_036556, VSP_036557;
CC       Name=9;
CC         IsoId=P22694-9; Sequence=VSP_043372;
CC       Name=10;
CC         IsoId=P22694-10; Sequence=VSP_017366, VSP_046238;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is most abundant in the brain, with low
CC       level expression in kidney. Isoform 2 is predominantly expressed in
CC       thymus, spleen and kidney. Isoform 3 and isoform 4 are only expressed
CC       in the brain. {ECO:0000269|PubMed:11589697}.
CC   -!- PTM: Asn-3 is partially deaminated to Asp giving rise to 2 major
CC       isoelectric variants, called CB and CA respectively. {ECO:0000250}.
CC   -!- DISEASE: Cardioacrofacial dysplasia 2 (CAFD2) [MIM:619143]: An
CC       autosomal dominant disease characterized by dysmorphic facial features,
CC       congenital cardiac defects, primarily common atrium or atrioventricular
CC       septal defect, and limb anomalies, including short limbs, brachydactyly
CC       and postaxial polydactyly. CAFD2 patients may show developmental delay
CC       of variable severity, intellectual disability, autistic features and
CC       focal seizures. {ECO:0000269|PubMed:33058759}. Note=The disease is
CC       caused by variants affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform 3]: Incomplete sequence. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 4]: Incomplete sequence. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 5]: Incomplete sequence. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. cAMP subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD92426.1; Type=Frameshift; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/prkacb/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M34181; AAA60170.1; -; mRNA.
DR   EMBL; BX537705; CAD97818.1; -; mRNA.
DR   EMBL; BX641026; CAE46017.1; -; mRNA.
DR   EMBL; AB209189; BAD92426.1; ALT_SEQ; mRNA.
DR   EMBL; CR936631; CAI56774.1; -; mRNA.
DR   EMBL; AK091420; BAG52356.1; -; mRNA.
DR   EMBL; AK296482; BAG59122.1; -; mRNA.
DR   EMBL; AK304375; BAG65213.1; -; mRNA.
DR   EMBL; DQ667174; ABG25919.1; -; Genomic_DNA.
DR   EMBL; AL359504; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL450063; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471097; EAW73248.1; -; Genomic_DNA.
DR   EMBL; BC016285; AAH16285.1; -; mRNA.
DR   EMBL; BC035058; AAH35058.1; -; mRNA.
DR   EMBL; AY927364; AAX19487.1; -; mRNA.
DR   EMBL; AY927365; AAX19488.1; -; mRNA.
DR   EMBL; AY927366; AAX19489.1; -; mRNA.
DR   EMBL; AY927367; AAX19490.1; -; mRNA.
DR   EMBL; AY927368; AAX19491.1; -; mRNA.
DR   EMBL; AF538872; AAN16454.1; -; Genomic_DNA.
DR   CCDS; CCDS55609.1; -. [P22694-9]
DR   CCDS; CCDS55610.1; -. [P22694-7]
DR   CCDS; CCDS55611.1; -. [P22694-10]
DR   CCDS; CCDS691.1; -. [P22694-1]
DR   CCDS; CCDS692.1; -. [P22694-8]
DR   CCDS; CCDS693.1; -. [P22694-2]
DR   CCDS; CCDS72813.1; -. [P22694-3]
DR   CCDS; CCDS72815.1; -. [P22694-6]
DR   PIR; A34724; OKHUCB.
DR   RefSeq; NP_001229786.1; NM_001242857.2. [P22694-9]
DR   RefSeq; NP_001229787.1; NM_001242858.2. [P22694-3]
DR   RefSeq; NP_001229788.1; NM_001242859.2. [P22694-7]
DR   RefSeq; NP_001229789.1; NM_001242860.2. [P22694-6]
DR   RefSeq; NP_001229790.1; NM_001242861.2. [P22694-10]
DR   RefSeq; NP_001229791.1; NM_001242862.2.
DR   RefSeq; NP_001287844.1; NM_001300915.1.
DR   RefSeq; NP_001287845.1; NM_001300916.1.
DR   RefSeq; NP_001287846.1; NM_001300917.1.
DR   RefSeq; NP_002722.1; NM_002731.3. [P22694-1]
DR   RefSeq; NP_891993.1; NM_182948.3. [P22694-2]
DR   RefSeq; NP_997461.1; NM_207578.2. [P22694-8]
DR   RefSeq; XP_005271076.1; XM_005271019.1.
DR   RefSeq; XP_006710821.1; XM_006710758.1.
DR   AlphaFoldDB; P22694; -.
DR   SMR; P22694; -.
DR   BioGRID; 111554; 126.
DR   IntAct; P22694; 83.
DR   MINT; P22694; -.
DR   STRING; 9606.ENSP00000359719; -.
DR   BindingDB; P22694; -.
DR   ChEMBL; CHEMBL2918; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB02482; Phosphonothreonine.
DR   DrugCentral; P22694; -.
DR   GuidetoPHARMACOLOGY; 1477; -.
DR   GlyGen; P22694; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P22694; -.
DR   MetOSite; P22694; -.
DR   PhosphoSitePlus; P22694; -.
DR   SwissPalm; P22694; -.
DR   BioMuta; PRKACB; -.
DR   DMDM; 125210; -.
DR   EPD; P22694; -.
DR   jPOST; P22694; -.
DR   MassIVE; P22694; -.
DR   MaxQB; P22694; -.
DR   PaxDb; P22694; -.
DR   PeptideAtlas; P22694; -.
DR   PRIDE; P22694; -.
DR   ProteomicsDB; 3296; -.
DR   ProteomicsDB; 54019; -. [P22694-1]
DR   ProteomicsDB; 54020; -. [P22694-2]
DR   ProteomicsDB; 54021; -. [P22694-3]
DR   ProteomicsDB; 54022; -. [P22694-4]
DR   ProteomicsDB; 54023; -. [P22694-5]
DR   ProteomicsDB; 54024; -. [P22694-6]
DR   ProteomicsDB; 54025; -. [P22694-7]
DR   ProteomicsDB; 54026; -. [P22694-8]
DR   ProteomicsDB; 54027; -. [P22694-9]
DR   Antibodypedia; 4160; 418 antibodies from 35 providers.
DR   DNASU; 5567; -.
DR   Ensembl; ENST00000370682.7; ENSP00000359716.3; ENSG00000142875.20. [P22694-7]
DR   Ensembl; ENST00000370685.7; ENSP00000359719.3; ENSG00000142875.20. [P22694-2]
DR   Ensembl; ENST00000370688.7; ENSP00000359722.3; ENSG00000142875.20. [P22694-8]
DR   Ensembl; ENST00000370689.6; ENSP00000359723.2; ENSG00000142875.20. [P22694-1]
DR   Ensembl; ENST00000394839.6; ENSP00000378315.2; ENSG00000142875.20. [P22694-10]
DR   Ensembl; ENST00000446538.5; ENSP00000401252.2; ENSG00000142875.20. [P22694-9]
DR   Ensembl; ENST00000610703.4; ENSP00000481980.1; ENSG00000142875.20. [P22694-3]
DR   Ensembl; ENST00000614872.4; ENSP00000479722.1; ENSG00000142875.20. [P22694-6]
DR   GeneID; 5567; -.
DR   KEGG; hsa:5567; -.
DR   MANE-Select; ENST00000370685.7; ENSP00000359719.3; NM_182948.4; NP_891993.1. [P22694-2]
DR   UCSC; uc001dji.4; human. [P22694-1]
DR   CTD; 5567; -.
DR   DisGeNET; 5567; -.
DR   GeneCards; PRKACB; -.
DR   HGNC; HGNC:9381; PRKACB.
DR   HPA; ENSG00000142875; Low tissue specificity.
DR   MalaCards; PRKACB; -.
DR   MIM; 176892; gene.
DR   MIM; 619143; phenotype.
DR   neXtProt; NX_P22694; -.
DR   OpenTargets; ENSG00000142875; -.
DR   PharmGKB; PA33749; -.
DR   VEuPathDB; HostDB:ENSG00000142875; -.
DR   eggNOG; KOG0616; Eukaryota.
DR   GeneTree; ENSGT00940000161169; -.
DR   HOGENOM; CLU_000288_63_5_1; -.
DR   InParanoid; P22694; -.
DR   OMA; GNARYNK; -.
DR   OrthoDB; 963519at2759; -.
DR   PhylomeDB; P22694; -.
DR   TreeFam; TF313399; -.
DR   BRENDA; 2.7.11.11; 2681.
DR   PathwayCommons; P22694; -.
DR   Reactome; R-HSA-111931; PKA-mediated phosphorylation of CREB.
DR   Reactome; R-HSA-163358; PKA-mediated phosphorylation of key metabolic factors.
DR   Reactome; R-HSA-163560; Triglyceride catabolism.
DR   Reactome; R-HSA-163615; PKA activation.
DR   Reactome; R-HSA-164378; PKA activation in glucagon signalling.
DR   Reactome; R-HSA-180024; DARPP-32 events.
DR   Reactome; R-HSA-381676; Glucagon-like Peptide-1 (GLP1) regulates insulin secretion.
DR   Reactome; R-HSA-392517; Rap1 signalling.
DR   Reactome; R-HSA-422356; Regulation of insulin secretion.
DR   Reactome; R-HSA-432040; Vasopressin regulates renal water homeostasis via Aquaporins.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-HSA-442720; CREB1 phosphorylation through the activation of Adenylate Cyclase.
DR   Reactome; R-HSA-5610780; Degradation of GLI1 by the proteasome.
DR   Reactome; R-HSA-5610783; Degradation of GLI2 by the proteasome.
DR   Reactome; R-HSA-5610785; GLI3 is processed to GLI3R by the proteasome.
DR   Reactome; R-HSA-5610787; Hedgehog 'off' state.
DR   Reactome; R-HSA-5621575; CD209 (DC-SIGN) signaling.
DR   Reactome; R-HSA-5687128; MAPK6/MAPK4 signaling.
DR   Reactome; R-HSA-8853659; RET signaling.
DR   Reactome; R-HSA-8963896; HDL assembly.
DR   Reactome; R-HSA-9010642; ROBO receptors bind AKAP5.
DR   Reactome; R-HSA-9634597; GPER1 signaling.
DR   Reactome; R-HSA-9634600; Regulation of glycolysis by fructose 2,6-bisphosphate metabolism.
DR   Reactome; R-HSA-9660821; ADORA2B mediated anti-inflammatory cytokines production.
DR   Reactome; R-HSA-9664323; FCGR3A-mediated IL10 synthesis.
DR   Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production.
DR   SABIO-RK; P22694; -.
DR   SignaLink; P22694; -.
DR   SIGNOR; P22694; -.
DR   BioGRID-ORCS; 5567; 19 hits in 1110 CRISPR screens.
DR   ChiTaRS; PRKACB; human.
DR   GeneWiki; PRKACB; -.
DR   GenomeRNAi; 5567; -.
DR   Pharos; P22694; Tchem.
DR   PRO; PR:P22694; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; P22694; protein.
DR   Bgee; ENSG00000142875; Expressed in endothelial cell and 211 other tissues.
DR   ExpressionAtlas; P22694; baseline and differential.
DR   Genevisible; P22694; HS.
DR   GO; GO:0005952; C:cAMP-dependent protein kinase complex; TAS:UniProtKB.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0097546; C:ciliary base; TAS:Reactome.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0004679; F:AMP-activated protein kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0004691; F:cAMP-dependent protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:Reactome.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IDA:UniProtKB.
DR   GO; GO:0007188; P:adenylate cyclase-modulating G protein-coupled receptor signaling pathway; TAS:UniProtKB.
DR   GO; GO:0034380; P:high-density lipoprotein particle assembly; TAS:Reactome.
DR   GO; GO:1901621; P:negative regulation of smoothened signaling pathway involved in dorsal/ventral neural tube patterning; IEA:Ensembl.
DR   GO; GO:0001843; P:neural tube closure; IEA:Ensembl.
DR   GO; GO:0010737; P:protein kinase A signaling; IBA:GO_Central.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0070613; P:regulation of protein processing; IEA:Ensembl.
DR   GO; GO:0003091; P:renal water homeostasis; TAS:Reactome.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   CDD; cd14209; STKc_PKA; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR044109; STKc_PKA.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; cAMP; Cell membrane; Cytoplasm;
KW   Disease variant; Kinase; Lipoprotein; Membrane; Myristate;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|PubMed:25255805"
FT   CHAIN           2..351
FT                   /note="cAMP-dependent protein kinase catalytic subunit
FT                   beta"
FT                   /id="PRO_0000086060"
FT   DOMAIN          44..298
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          299..351
FT                   /note="AGC-kinase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00618"
FT   ACT_SITE        167
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         50..58
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         73
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         3
FT                   /note="Deamidated asparagine"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         11
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P05132"
FT   MOD_RES         69
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P68181"
FT   MOD_RES         140
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P05132"
FT   MOD_RES         198
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P05132"
FT   MOD_RES         322
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P68182"
FT   MOD_RES         331
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P05132"
FT   MOD_RES         339
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P68182"
FT   LIPID           2
FT                   /note="N-myristoyl glycine"
FT                   /evidence="ECO:0000269|PubMed:25255805"
FT   VAR_SEQ         1..16
FT                   /note="MGNAATAKKGSEVESV -> MAAYREPPCNQYTGTTTALQKLEGFASRLFHR
FT                   HSKGTAHDQKTALENDSLHFSEHTALWDRSM (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:11589697,
FT                   ECO:0000303|PubMed:17974005"
FT                   /id="VSP_017364"
FT   VAR_SEQ         1..15
FT                   /note="MGNAATAKKGSEVES -> MSARKSSDASACSSSEISDSF (in isoform
FT                   6)"
FT                   /evidence="ECO:0000303|PubMed:11589697, ECO:0000303|Ref.3"
FT                   /id="VSP_017365"
FT   VAR_SEQ         1..15
FT                   /note="MGNAATAKKGSEVES -> MGLSRKSSDASACSSSEISDSF (in
FT                   isoform 9)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_043372"
FT   VAR_SEQ         1..14
FT                   /note="MGNAATAKKGSEVE -> MSARKSSDASACSSSEI (in isoform 5
FT                   and isoform 10)"
FT                   /evidence="ECO:0000303|PubMed:11589697,
FT                   ECO:0000303|PubMed:14702039"
FT                   /id="VSP_017366"
FT   VAR_SEQ         1..14
FT                   /note="MGNAATAKKGSEVE -> MGLSRKSSDASACSSSEI (in isoform 7)"
FT                   /evidence="ECO:0000303|PubMed:17974005"
FT                   /id="VSP_017367"
FT   VAR_SEQ         1..13
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:11589697"
FT                   /id="VSP_017368"
FT   VAR_SEQ         1..12
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:11589697,
FT                   ECO:0000303|PubMed:14702039"
FT                   /id="VSP_017369"
FT   VAR_SEQ         13..16
FT                   /note="VESV -> MGLL (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:11589697,
FT                   ECO:0000303|PubMed:14702039"
FT                   /id="VSP_017370"
FT   VAR_SEQ         14
FT                   /note="E -> M (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:11589697"
FT                   /id="VSP_017371"
FT   VAR_SEQ         79..111
FT                   /note="Missing (in isoform 10)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_046238"
FT   VAR_SEQ         256..257
FT                   /note="VR -> NF (in isoform 8)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_036556"
FT   VAR_SEQ         258..351
FT                   /note="Missing (in isoform 8)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_036557"
FT   VARIANT         54
FT                   /note="S -> L (in CAFD2)"
FT                   /evidence="ECO:0000269|PubMed:33058759"
FT                   /id="VAR_085199"
FT   VARIANT         88
FT                   /note="H -> N (in CAFD2)"
FT                   /evidence="ECO:0000269|PubMed:33058759"
FT                   /id="VAR_085200"
FT   VARIANT         88
FT                   /note="H -> R (in CAFD2; increased sensitivity to cAMP
FT                   activation; dbSNP:rs768056300)"
FT                   /evidence="ECO:0000269|PubMed:33058759"
FT                   /id="VAR_085201"
FT   VARIANT         106
FT                   /note="R -> Q (in dbSNP:rs36117118)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040594"
FT   VARIANT         235
FT                   /note="G -> R (in CAFD2; increased sensitivity to cAMP
FT                   activation; decreased interaction with regulatory subunits
FT                   PRKAR1A and PRKAR2B)"
FT                   /evidence="ECO:0000269|PubMed:33058759"
FT                   /id="VAR_085202"
FT   CONFLICT        80
FT                   /note="V -> G (in Ref. 3; CAI56774)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        159
FT                   /note="H -> N (in Ref. 8; AAH35058)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        163
FT                   /note="L -> I (in Ref. 8; AAH35058)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        233
FT                   /note="A -> V (in Ref. 3; CAI56774)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        261
FT                   /note="H -> N (in Ref. 8; AAH35058)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   351 AA;  40623 MW;  5C7443FBBA1C9BEC CRC64;
     MGNAATAKKG SEVESVKEFL AKAKEDFLKK WENPTQNNAG LEDFERKKTL GTGSFGRVML
     VKHKATEQYY AMKILDKQKV VKLKQIEHTL NEKRILQAVN FPFLVRLEYA FKDNSNLYMV
     MEYVPGGEMF SHLRRIGRFS EPHARFYAAQ IVLTFEYLHS LDLIYRDLKP ENLLIDHQGY
     IQVTDFGFAK RVKGRTWTLC GTPEYLAPEI ILSKGYNKAV DWWALGVLIY EMAAGYPPFF
     ADQPIQIYEK IVSGKVRFPS HFSSDLKDLL RNLLQVDLTK RFGNLKNGVS DIKTHKWFAT
     TDWIAIYQRK VEAPFIPKFR GSGDTSNFDD YEEEDIRVSI TEKCAKEFGE F
//
